Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Type 2 Diabetes
Interventions
DRUG

Long-acting bedtime insulin detemir (Levemir)

This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.

DRUG

Insulin detemir and pre-meal insulin aspart.

This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.

Trial Locations (1)

78229-3900

The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital, San Antonio

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

VA Office of Research and Development

FED

collaborator

Novo Nordisk A/S

INDUSTRY

lead

University of Florida

OTHER